DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022106/S-007
NDA 022106/S-008
NDA 022106/S-009
NDA 022106/S-014

SUPPLEMENT APPROVAL

Janssen Research & Development, LLC
Attention: Gary Lewis
Associate Director, Global Regulatory Affairs
920 US Route 202
Raritan, NJ 08869

Dear Mr. Lewis:

Please refer to your Supplemental New Drug Applications (sNDA) dated May 22, 2009 (S-007), February 3, 2010 (S-008), September 21, 2010 (S-009), and January 16, 2013 (S-014), received May 22, 2009, February 3, 2010, September 22, 2010, and January 16, 2013, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DORIBAX (doripenem) for Injection.

We acknowledge receipt of your amendments dated May 21, 2010 (S-007) and November 29, 2010 (S-008), May 31, June 7, and October 23, 2012 (S-007, S-008, S-009), and March 25, April 4, and April 9, 2013 (S-007, S-008, S-009, and S-014).

The May 31, 2012, submission constituted a complete response to our May 31, 2011, action letter for supplements 007, 008, and 009.

S-007, a "Changes Being Effected" labeling supplement provides for addition of Stevens-Johnson Syndrome and Toxic epidermal necrolysis to the **ADVERSE REACTIONS** section, **Postmarketing Experience** subsection (6.2) and for minor editorial revisions.

S-008, a "Changes Being Effected" labeling supplement provides for the following:

HIGHLIGHTS section, **RECENT MAJOR CHANGES**

- Deletion of Warnings and Precautions, Interaction with Valproic Acid (5.2)

FULL PRESCRIBING INFORMATION

- **ADVERSE REACTIONS s**ection, **Adverse Reactions from Clinical Trials** subsection (6.1): revisions to Table 4.
- **ADVERSE REACTIONS** section**, Postmarketing Experience** subsection (6.2): addition of the term thrombocytopenia.

S-009, a "Prior Approval" labeling supplement provides for the following:

- **ADVERSE REACTIONS** section, **Adverse Reactions from Clinical Trials** subsection (6.1): addition of information about the greater incidence of skin rash with higher doses of doripenem.

- **CLINICAL PHARMACOLOGY** section**, Pharmacokinetics, Excretion** subsection **(12.3):** updated information on the mean renal clearance of doripenem and the percentage of dose recovered in urine as unchanged drug.

S-014, a "Prior Approval" labeling supplement provides for the following:

HIGHLIGHTS section, **RECENT MAJOR CHANGES**

- **WARNINGS AND PRECAUTIONS** section: addition of Seizures (5.2)

FULL PRESCRIBING INFORMATION

- **WARNINGS AND PRECAUTIONS** section: addition of a new section on Seizures (5.2)
- **ADVERSE REACTIONS** section**, Postmarketing Experience** subsection (6.2): addition of the term seizures
- **PATIENT COUNSELING INFORMATION** (17)**:** addition of information regarding seizures

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, MD, Regulatory Project Manager, at (301) 796-0803.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, M.D., M.P.H.
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Package Insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
04/15/2013